<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02617082</url>
  </required_header>
  <id_info>
    <org_study_id>FDRT-BC004</org_study_id>
    <nct_id>NCT02617082</nct_id>
  </id_info>
  <brief_title>Partial Breast Irradiation for Low-risk Ductal Carcinoma In Situ After Breast-conserving Surgery</brief_title>
  <official_title>Phase II Study of Partial Breast Irradiation for Low-risk Ductal Carcinoma In Situ After Breast-conserving Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the feasibility and safety of partial breast irradiation
      for low risk DCIS after breast-conserving surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized clinical trials have demonstrated that the recurrence of DCIS is low and most of
      the recurrence occurs around the tumor bed. Besides, cosmetic outcomes are reported better in
      partial breast irradiation group compared to whole breast irradiation group. However, whether
      or not partial breast irradiation is safety in DCIS is still unknown. The purpose of this
      study is to evaluate the feasibility and safety of partial breast irradiation for low risk
      DCIS after breast-conserving surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>ipsilateral breast tumor recurrence</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>occurrence of contralateral breast tumor after PBI</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>radiation-induced toxicity of breast assessed by CTCAE v4.0</measure>
    <time_frame>baseline, 3 months, 6 months, and every half year to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>baseline，1，2，3，4，5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">828</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>partial breast irradiation</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>partial breast irradiation</intervention_name>
    <description>The prescription dose is 40.5Gy in 15 fractions in 3 weeks.</description>
    <arm_group_label>partial breast irradiation</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        DCIS breast cancer patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  18~65 years old

          -  Pathologically confirmed DCIS, low- or intermediate- grade DCIS: (lesions of ≤2.5 cm
             diameter, resection margins of at least 3 mm, nuclei grade: 1-2), high grade DCIS:
             (lesions of ≤1 cm diameter, resection margins of at least 3 mm, nuclei grade: 3)

          -  Treated with breast conserving surgery

          -  Tumor bed is labeled with Titanium clips

          -  No malignancy history

          -  ECOG score 0~1

          -  Written informed consent

        Exclusion Criteria:

          -  DCIS of both breast

          -  invasive breast cancer

          -  Multicentric disease

          -  Patients underwent mastectomy

          -  Previous radiation therapy of breast

          -  Medical contraindication for radiotherapy

          -  Pregnant or nursing

          -  suspicious calcification after surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoli Yu, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoli Yu, MD.PhD</last_name>
    <phone>+86 18017312388</phone>
    <email>stephanieyxl@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhaozhi Yang, MD.PhD</last_name>
    <phone>+86 18017317126</phone>
    <email>yzzhi2014@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoli Yu, MD,PhD</last_name>
      <phone>+86 13817893133</phone>
      <email>stephanieyxl@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiaofang Wang, MD</last_name>
      <phone>+86 18818211606</phone>
      <email>xiaofang0708@yeah.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2015</study_first_submitted>
  <study_first_submitted_qc>November 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2015</study_first_posted>
  <last_update_submitted>November 27, 2015</last_update_submitted>
  <last_update_submitted_qc>November 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xiaoli Yu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>partial breast irradiation</keyword>
  <keyword>DCIS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

